Diabetologia

Imai, E.; Chan, J.; Ito, S.; Yamasaki, T.; Kobayashi, F.; Haneda, M.; Makino, H.

doi: 10.1007/s00125-011-2325-zpmid: 21993710

Olmesartan was well tolerated but did not improve renal outcome on top of ACEI. Trial registration: ClinicalTrials.gov NCT00141453 Funding: The ORIENT study was supported by a research grant from Daiichi Sankyo.

Logue, J.; Walker, J.; Colhoun, H.; Leese, G.; Lindsay, R.; McKnight, J.; Morris, A.; Pearson, D.; Petrie, J.; Philip, S.; Wild, S.; Sattar, N.

doi: 10.1007/s00125-011-2313-3pmid:

Grote, V.; Rohrmann, S.; Nieters, A.; Dossus, L.; Tjønneland, A.; Halkjær, J.; Overvad, K.; Fagherazzi, G.; Boutron-Ruault, M.; Morois, S.; Teucher, B.; Becker, S.; Sluik, D.; Boeing, H.; Trichopoulou, A.;

Mehers, K.; Long, A.; Slik, A.; Aitken, R.; Nathwani, V.; Wong, F.; Bain, S.; Gill, G.; Roep, B.; Bingley, P.; Gillespie, K.

doi: 10.1007/s00125-011-2299-xpmid: 21909837

Locke, J.; Da Silva Xavier, G.; Rutter, G.; Harries, L.

doi: 10.1007/s00125-011-2290-6pmid: 21913056

We have identified a novel polyadenylation signal within TCF7L2 that can result in the production of isoforms that act to repress TCF/LEF-dependent target genes. These findings may provide new insights into the association of TCF7L2 with susceptibility to type 2 diabetes.

Samson, S.; Sathyanarayana, P.; Jogi, M.; Gonzalez, E.; Gutierrez, A.; Krishnamurthy, R.; Muthupillai, R.; Chan, L.; Bajaj, M.

doi: 10.1007/s00125-011-2317-zpmid: 21956711

In type 2 diabetes mellitus, combined pioglitazone and exenatide therapy is associated with a reduction in plasma FGF21 levels, as well as a greater decrease in hepatic fat than that achieved with pioglitazone therapy. In DIO mice, exendin-4 treatment reduces hepatic triacylglycerol and FGF21 protein, and enhances hepatic AMPK phosphorylation, suggesting an improvement of hepatic FGF21 resistance. Trial registration number: ClinicalTrials.gov NCT 01432405 Funding: American Diabetes Association, the Ron MacDonald Foundation at St Luke’s Episcopal Hospital, Amylin Pharmaceuticals, Eli-Lilly, NIH Molecular Medicine Scholars Training Grant, NIH Diabetes and Endocrinology Research Center (DERC) at Baylor College of Medicine, and the T.T. and W.F. Chao Foundation.